camrelizumab + anti-angiogenic tyrosine kinase inhibitors

This combination therapy involves the programmed cell death protein 1 (PD-1) inhibitor camrelizumab (Airuika) administered alongside anti-angiogenic tyrosine kinase inhibitors (TKIs) such as fruquintinib, regorafenib, or apatinib, often in conjunction with chemotherapy (e.g., irinotecan). It is being investigated in a Phase II clinical trial led by Zhejiang Cancer Hospital specifically for the treatment of metastatic colorectal mucinous adenocarcinoma (MAC), a subtype of colorectal cancer known for poor prognosis and resistance to standard therapies. Camrelizumab, developed by Jiangsu Hengrui Medicine, works by blocking the PD-1/PD-L1 pathway to restore T-cell antitumor activity, while the TKIs inhibit vascular endothelial growth factor receptors (VEGFR) to suppress tumor angiogenesis and potentially modulate the tumor microenvironment to enhance immunotherapy efficacy.

Brand names

Airuika

Other names

carilizumab + anti-angiogenic tkiscamrelizumab + fruquintinibcamrelizumab + regorafenibcamrelizumab + apatinibcamrelizumab + VEGFR TKIs